Роль липопротеина(а) в формировании сердечно-сосудистых заболеваний в детском возрасте


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В статье представлен анализ литературы, посвященной исследованию липопротеина (а) при сердечно-сосудистых заболеваниях у детей. Авторы демонстрируют научные работы о влиянии повышенного уровня липопротеина(а) на риск возникновения инсульта, атеросклероза сосудов и ранней ишемической болезни сердца.

Полный текст

Доступ закрыт

Об авторах

Д. И Садыкова

Казанский государственный медицинский университет

Казань, Россия

Л. Ф Галимова

Казанский государственный медицинский университет; Детская республиканская клиническая больница

Email: lilu1@inbox.ru
к.м.н., врач, ассистент кафедры госпитальной педиатрии 420138, Россия, Казань, ул. Оренбургский тракт, 140

Е. С Сластникова

Казанский государственный медицинский университет; Детская республиканская клиническая больница

Казань, Россия

Н. Э Усова

Казанский государственный медицинский университет; Детская республиканская клиническая больница

Казань, Россия

Ч. Д Халиуллина

Казанский государственный медицинский университет

Казань, Россия

Список литературы

  1. Mathers C.D., Bernard C., Iburg K., et al. Global Burden of Disease in 2002: data sources, methods and results. Global Programme on Evidence for Health Policy Discussion Paper No. 54 World Health Organization December 2003. URL: https://www.who.int/healthinfo/paper54.pdf
  2. Qayum O, Alshami N., Ibezim C.F., et al. Lipoprotein (a): Examination of Cardiovascular Risk in a Pediatric Referral Population. Pediatr Cardiol. 2018;39(8):1540-46. doi: 10.1007/s00246-018-1927-3.
  3. McNeal C.J. Lipoprotein (a): Its relevance to the pediatric population. J Clin Lipidol. 2015;9(5):S57-66. doi: 10.1016/j.jacl.2015.07.00.
  4. Kronenberg F, Kronenberg M.F, Kiechl S., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulaton. 1999;100:1154-60. doi: 10.1161/01.CIR.100.11.1154.
  5. Maranhao R.C., Carvalho P.O., Strunz C.C., Pileggi F. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103:76-84. doi: 10.5935/abc.20140101.
  6. Van der Valk F.M., Bekkering S., Kroon J., et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611-24. doi: 10.1161/CIRCU LATIONAHA.116.02083 8.
  7. Ferretti G, Bacchetti T., Johnston, T.P, et al. Lipoprotein(a): A missing culprit in the management of athero-thrombosis? J Cell Physiol. 2017;233(4):2966-81. Doi: 10.1002/ jcp.26050.
  8. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412-23. Doi: 10.1001/ jama.2009.1063.
  9. Malaguarnera M., Vacante M., Russo C., et al. Lipoprotein(a) in cardiovascular diseases. BioMed Res Internat. 2013;2013:650989. doi: 10.1155/2013/650989.
  10. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J. 2010;31(23):2844-53. doi: 10.1093/eurheartj/ehq386.
  11. Nicholls S.J., Tang W.H., Scoffone H., et al. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res. 2010;51(10):3055-61. Doi: 10.1194/ jlr.M008961.
  12. Roach E.S., Golomb M.R., Adams R., et al. American Heart Association Stroke Council; Council on Cardiovascular Disease in the Young. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008;39:2644-91. Doi: 10.1161/ STROKEAHA.108.189696.
  13. Sultan S.M., Schupf N., Dowling M.M., et al. Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke. Stroke. 2014;9:79-87. doi: 10.1111/ijs.12136.
  14. Kenet G., Leutkhoff L.K., Albisetti M., et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation. 2010;121:1838-47. Doi: 10.1161/ CIRCULATIONAHA.109.913673.
  15. Goldenberg N.A., Bernard T.J., Hillhouse J., et al. Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematol. 2013;98:802-7. doi: 10.3324/haematol.2012.073833.
  16. Lakshminarayan D., Elajami T.K., Devabhaktuni S., Welty F.K. Ischemic stroke in a young adult with extremely elevated lipoprotein(a): A case report and review of literature. J Clin Lipidol. 2016;10(5):1266-71. Doi: 10.1016/j. jacl.2016.06.012.
  17. Зуева И.Б., Бараташвили Г. Г, Кривоносов Д.С. и др. Современные представления о роли липопротеина (а) в развитии сердечно-сосудистых событий. Возможности терапии. Артериальная гипертензия. 2016;22(3):232-43. @@Zueva I.B., Baratashvili G.G., Krivonosov D.S., et al. Modern concepts of the role of lipoprotein (a) in the development of cardiovascular events. Possibilities of therapy. Arterial'naya gipertenziya. 2016;22(3):232-43. (In Russ.).
  18. De Simone M., Verrotti A., Cappa M., et al. Lipoprotein (a) in childhood: correlations with family history of cardiovascular disease. J Endocrinol Invest. 2003;26:414-19. doi: 10.1007/BF03345196.
  19. Glowinska B., Urban M., Koput A. Cardiovascular risk factors in children with obesity, hypertension and diabetes: lipoprotein(a) levels and body mass index correlate with family history of cardiovascular disease. Eur J Pediatr. 2002;161:511-18. doi: 10.1007/s00431-002-1040-7.
  20. Guardamagna O., Abello F, Anfossi G., Pirro M. Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias. J Pediatr. 2011;159:314-19. doi: 10.1016/j.jpeds.2011.01.038.
  21. Gaeta G., Cuomo S., Capozzi G., et al. Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction. Nutr Metab Cardiovasc Dis. 2008;18:492-96. doi: 10.1016/j.numec d.2007.03.006.
  22. Lapinliemu J., Raitakari O.T., Lapinleimu H., et al. High lipoprotein(a) concentrations are associated with impaired endothelial function in children. J Pediatr. 2015;166:947-52. Doi: 10.1016/j. jpeds.2014.12.051.
  23. Narverud I., Retters l. K., Iversen P O., et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: A literature review. Atherosclerosis. 2014;235(2):299-309. doi: 10.1016/j.atherosclerosis.2014.05.917.
  24. Ryu S.K., Hutten B.A., Vissers M.N., et al. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Clin Lipidol. 2011;5(1):50-6. doi: 10.1016/j.jacl.2010.11.001.
  25. Narverud I., Halvorsen B., Nenseter M.S., et al. Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia. J Intern Med. 2013;273:69- 78. doi: 10.1111/j.1365-2796.2012.02584.x.
  26. Stubiger G., Aldover-Macasaet E., Bicker W., et al. Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QIT-TOFMS/ MS. Atherosclerosis. 2012;224:177-86. doi: 10.1016/j.atherosclerosis.2012.06.010.
  27. Widhalm K., Genser D. Elevated levels of lipoprotein (a) in children with familial hypercholesterolemia. Wien Klin Wochenschr. 1994;106:197-200.
  28. Vaya A., Martinez M., Dalmau J., et al. Hemorheological changes in children with familial hypercholesterolemia. Clin Hemorheol Microcirc. 1996;16:549-57.
  29. Sorensen K.E., Celermajer D.S., Georgakopoulos D., et al. Impairment of endotheliumdependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 1994;93:50-5. doi: 10.1172/JCI11698.
  30. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi: 10.1093/eurheartj/ehz455.
  31. Stefanutti C., Julius U., Watts G.F., et al. Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol. 2017;11(4):858-871.е3. doi: 10.1016/j. jacl.2017.04.114.
  32. Grundy S.M., Stone N., Bailey A.L., et al. 2018 NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:3168-209. dot 10.W16/j.jacc.2018.11.002.
  33. Anderson T.J., Gregoire J, Pearson G.J., et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in 545 the adult. Can J Cardiol. 2016;32(11):1263-82. dot 10.1016/j. cjca.2016.07.510.
  34. Cegla J., Neely R.D.G., France M, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 2019;291:62-70. doi: 10.1016/j.atherosclerosis.2019.10.011.
  35. Tsimikas S, Stroes E.S.G. The dedicated “Lp(a) clinic": A concept whose time has arrived? Atherosclerosis. 2020;300:1-9. Doi: 10.1016/j. atherosclerosis.2020.03.003.
  36. Yeang C, Witztum J.L., Tsimikas S. “LDL-C"=LDL-C+Lp(a)-C: implications of achieved ultralow LDL-C levels in the proprotein convertase subtilisin/ kexin type 9 era of potent LDL-C lowering, Curr Opin Lipidol. 2015;26(3):169-78. doi: 10.1097/ M0L.0000000000000171.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2021

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах